A research-based resource from Parasym, creators of the Nuropod wearable device, explains blood pressure variability, the reflex that corrects pressure shifts, and how research on Parasym’s AVNT™ waveform has examined cardiovascular measures.
-- The team behind Nuropod and neurotechnology research company Parasym has published a research-based resource explaining why blood pressure readings move throughout the day and how the vagus nerve helps correct those shifts. The vagus nerve is the nerve that carries signals between the brain and organs including the heart. Released on September 24, 2026, the resource focuses on blood pressure variability, a measure of how much readings move across a day, which cardiovascular research examines separately from the average reading.
The topic is relevant to a large share of American adults. According to the American Heart Association’s 2026 Heart Disease and Stroke Statistics, about 125.9 million U.S. adults, or 47.3%, have high blood pressure, and the association reports that only about one in four have it under control. Home and clinic readings are central to tracking blood pressure, and the Nuropod resource explains why those numbers can differ from one measurement to the next.
According to the resource, the nervous system adjusts blood pressure continuously through the baroreflex. In this feedback loop, stretch sensors in the large arteries detect rising pressure, and signals carried by the vagus nerve slow the heart until pressure returns to its usual range. Because this correction happens without any conscious effort, two readings taken an hour apart can differ in the same person on the same day. Blood pressure variability reflects how quickly each shift is corrected, which is why two people with the same average reading can show very different patterns across a day.
The resource also describes how two sides of the nervous system shape the cardiovascular system. The fight-or-flight side raises heart rate and tightens blood vessels, while the rest-and-digest side slows the heart and returns both toward baseline once a demand has passed. When stress keeps the fight-or-flight side active longer than needed, heart rate and pressure take longer to settle.
“When people struggle to relax, rest adequately and recover from stressful events, it might be a sign the body has become less resilient,” said Dr. Elisabetta Burchi, Translational Research Lead at Parasym. “That could be underpinned by disruption in the stress regulation mechanisms.”
The resource also covers heart rate variability (HRV), which measures how much the time between heartbeats varies and reflects how well the body handles stress. It notes that HRV is not a direct measure of vagus nerve activity.
The resource keeps general research on vagus nerve stimulation separate from findings tied to a specific technology, noting that results belong to the waveform that produced them. Research using Parasym’s AVNT technology, the proprietary waveform inside Nuropod, reports outcomes measured under research conditions. In clinical studies, blood pressure variability fell by an average of 52%. In clinical studies, blood vessel flexibility improved by an average of 50%.
Nuropod is a wearable vagus nerve stimulation device that clips onto the tragus, where the vagus nerve reaches the skin of the ear, and delivers gentle electrical pulses using Parasym’s proprietary AVNT waveform. The device is designed to be used daily alongside existing care.
About Nuropod
Launched in the United States in September 2025, Nuropod is a wearable vagus nerve stimulation device built around Parasym’s proprietary AVNT™ waveform. The technology is supported by more than 60 completed clinical studies, more than 100 ongoing studies, more than 150 research partners and over 10 years of research and development. Nuropod is FCC compliant and is a wellness device, not a medical device.
The full resource is available at https://nuropod.com/blogs/articles/vagus-nerve-impact-on-blood-pressure-heart-nervous-system-connection
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as guaranteed individual outcomes. Nuropod is classified by the FDA as a non-designated risk device and is not intended to diagnose, treat, cure, or prevent any disease.
Contact Info:
Name: PR Team
Email: Send Email
Organization: Nuropod by Parasym
Address: 2108 N Street, Sacramento, California 95816, United States
Website: https://nuropod.com/
Source: PressCable
Release ID: 89208315
If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.
